Clinical trial data published in the New England Journal of Medicine found that tirzepatide produced meaningfully greater weight loss than semaglutide on average in patients with obesity
Participants attended an informed consent, medical history and treatment initiation visit (V1, week 0), several intermediate visits depending on the local clinical practice (V2.X, weeks 133) and an EOS visit (V3, weeks 3444) to assess efficacy and safety parameters, and PROs
Wils P, Caron B, DAmico F, Danese S, Peyrin-Biroulet L
CoraDoc operates in all 50 states through its network of licensed telehealth providers
Tirzepatide for the treatment of obstructive sleep apnea and obesity (SURMOUNT-OSA)